 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(ECNS) -- HuaTangNing (Dorzagliatin Tablets), a first-in-class glucokinase activator (GKA) for Type 2 diabetes (T2D) treatment, was approved by China’s National Medical Products Administration on Sunday. This drug can control blood glucose levels and is expected to relieve diabetes fundamentally. Clinical trials have shown HuaTangNing in combination with empagliflozin (SGLT-2 inhibitor) and sitagliptin (DPP-IV inhibitor) is expected to better improve blood glucose control and pancreatic islet functions in T2D patients than either empagliflozin or sitagliptin taken alone. This independently-developed Chinese drug has become a new choice of T2D patients. |
 |
 |
 |
 |
 |
|
|
